Ursa Brown‐Glaberman

1.2k total citations
38 papers, 382 citations indexed

About

Ursa Brown‐Glaberman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Ursa Brown‐Glaberman has authored 38 papers receiving a total of 382 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in Ursa Brown‐Glaberman's work include Cancer Treatment and Pharmacology (15 papers), HER2/EGFR in Cancer Research (14 papers) and Advanced Breast Cancer Therapies (12 papers). Ursa Brown‐Glaberman is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), HER2/EGFR in Cancer Research (14 papers) and Advanced Breast Cancer Therapies (12 papers). Ursa Brown‐Glaberman collaborates with scholars based in United States, Spain and France. Ursa Brown‐Glaberman's co-authors include Melanie Royce, Alison Stopeck, Zoneddy Dayao, William J. Gradishar, Pavani Chalasani, Hope S. Rugo, Antonio C. Wolff, Jane B. Trepel, Clifford A. Hudis and Roisín M. Connolly and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Ursa Brown‐Glaberman

34 papers receiving 380 citations

Peers

Countries citing papers authored by Ursa Brown‐Glaberman

Since Specialization

Citations

This map shows the geographic impact of Ursa Brown‐Glaberman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ursa Brown‐Glaberman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ursa Brown‐Glaberman more than expected).

Fields of papers citing papers by Ursa Brown‐Glaberman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ursa Brown‐Glaberman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ursa Brown‐Glaberman. The network helps show where Ursa Brown‐Glaberman may publish in the future.

Co-authorship network of co-authors of Ursa Brown‐Glaberman

This figure shows the co-authorship network connecting the top 25 collaborators of Ursa Brown‐Glaberman. A scholar is included among the top collaborators of Ursa Brown‐Glaberman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ursa Brown‐Glaberman. Ursa Brown‐Glaberman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First‐in‐human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors 2025 ·Cancer ·Timothy A. Yap, Olivier Rixe, Capucine Baldini, Ursa Brown‐Glaberman, (unknown), David S. Hong, Christophe Massard, Jameel Muzaffar, Andreea Varga, Emrullah Yilmaz, (unknown), (unknown), Yi Liu, Matthew Hruska, Henry Zhao, (unknown), Solmaz Sahebjam	2
2	Developing questions to assess and measure patients’ perceived survival benefit from adjuvant endocrine therapy in breast cancer: a mixed methods pilot study 2024 ·Clinical and Experimental Medicine ·Bernard Tawfik, (unknown), Ursa Brown‐Glaberman, (unknown), M. Lee Van Horn, (unknown), Zoneddy Dayao, V. Shane Pankratz, Andrew L. Sussman, Dolores D. Guest	0
3	Abstract OT1-03-06: Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress) 2023 ·Cancer Research ·Patrick M. Dillon, Reva Basho, Hyo S. Han, Hans‐Christian Kolberg, Katherine Tkaczuk, (unknown), María Gión, (unknown), Jane Meisel, Timothy Pluard, (unknown), Mafalda Oliveira, Ursa Brown‐Glaberman, Erica Stringer-Reasor, Luís Manso, Sherko Küemmel, (unknown), (unknown), (unknown), Valentina Boni	3
4	A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome in breast cancer patients: Alliance A22_Pilot2 2023 ·Supportive Care in Cancer ·Bernard Tawfik, Zoneddy Dayao, Ursa Brown‐Glaberman, V. Shane Pankratz, Jacqueline M. Lafky, Charles L. Loprinzi, Debra L. Barton	7
5	A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony-Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia 2022 ·Journal of Clinical Oncology ·Dawn L. Hershman, Aasthaa Bansal, Sean D. Sullivan, William E. Barlow, Kathryn B. Arnold, Kate Watabayashi, (unknown), Nguyet Le‐Lindqwister, (unknown), Ursa Brown‐Glaberman, Robert J. Behrens, Victor G. Vogel, (unknown), Scott D. Ramsey	3
6	Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial 2022 ·Breast Cancer Research and Treatment ·Mario Campone, Michelino De Laurentiis, Claudio Zamagni, (unknown), Mariëtte J Agterof, Ursa Brown‐Glaberman, Markéta Palácová, Sanjoy Chatterjee, (unknown), (unknown), Miguel Martín	9
7	Southwest Harvest for Health: An Adapted Mentored Vegetable Gardening Intervention for Cancer Survivors 2021 ·Nutrients ·Cindy K. Blair, Prajakta Adsul, Dolores D. Guest, Andrew L. Sussman, Linda S. Cook, Elizabeth Harding, (unknown), (unknown), Ellen Burgess, (unknown), Ursa Brown‐Glaberman, (unknown), (unknown), Zoneddy Dayao, V. Shane Pankratz, Sally M. Davis, Wendy Demark‐Wahnefried	11
8	E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group 2021 ·Journal of Clinical Oncology ·Roisín M. Connolly, Fengmin Zhao, Kathy D. Miller, Min-Jung Lee, Richard Piekarz, Karen L. Smith, Ursa Brown‐Glaberman, (unknown), Bryan A. Faller, Adedayo A. Onitilo, Mark E. Burkard, G. Thomas Budd, Ellis Levine, Melanie Royce, Peter A. Kaufman, Alexandra Thomas, Jane B. Trepel, Antonio C. Wolff, Joseph A. Sparano	76
9	Southwest Harvest for Health: Adapting a mentored vegetable gardening intervention for cancer survivors in the southwest 2021 ·Contemporary Clinical Trials Communications ·Cindy K. Blair, Elizabeth Harding, Prajakta Adsul, (unknown), Dolores D. Guest, (unknown), Andrew L. Sussman, (unknown), Linda S. Cook, (unknown), Zoneddy Dayao, Ursa Brown‐Glaberman, (unknown), V. Shane Pankratz, (unknown), Sally M. Davis, Wendy Demark‐Wahnefried	5
10	Abstract PS10-03: Interim safety and efficacy analysis of phase IB / II clinical trial of tucatinib, palbociclib and letrozole in patients with hormone receptor and HER2-positive metastatic breast cancer 2021 ·Cancer Research ·Elena Shagisultanova, William J. Gradishar, Ursa Brown‐Glaberman, Pavani Chalasani, Andrew Brenner, Alison Stopeck, José Mayordomo, Jennifer R. Diamond, Peter Kabos, Virginia F. Borges	5
11	A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer 2021 ·Clinical Breast Cancer ·(unknown), Isaac Jenkins, Hannah M. Linden, Brenda F. Kurland, Julie R. Gralow, (unknown), Georgiana K. Ellis, Qian Wu, Eve T. Rodler, Pavani Chalasani, Xiaoyu Chai, (unknown), (unknown), Alison Stopeck, Ursa Brown‐Glaberman, Jennifer M. Specht	10
12	Abstract GS4-02: E2112: Randomized phase 3 trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group 2021 ·Cancer Research ·Roisín M. Connolly, Fengmin Zhao, Kathy D. Miller, Min-Jung Lee, Richard Piekarz, Karen L. Smith, Ursa Brown‐Glaberman, (unknown), Bryan A. Faller, Adedayo A. Onitilo, Mark E. Burkard, G. Thomas Budd, Ellis Levine, Melanie Royce, Peter A. Kaufman, Alexandra Thomas, Jane B. Trepel, Antonio C. Wolff, Joseph A. Sparano	2
13	357TiP SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer 2020 ·Annals of Oncology ·Javier Cortés, Sami Diab, Reva Basho, Mafalda Oliveira, Timothy Pluard, Carlos Alemany, Ursa Brown‐Glaberman, Jane Meisel, Valentina Boni, Rajni Sinha, (unknown), Johannes Ettl, Sherko Küemmel, (unknown), Yong Wha Moon, Rafael Villanueva-Vázquez, Rachel Wuerstlein, (unknown), (unknown), Heather Han	5
14	Predicting breast cancer response to neoadjuvant chemotherapy based on tumor vascular features in needle biopsies 2019 ·JCI Insight ·(unknown), Ursa Brown‐Glaberman, Zhihui Wang, Reed Selwyn, Colin M. Wilson, (unknown), Lesley Lomo, (unknown), (unknown), Renata Pasqualini, Wadih Arap, C. Jeffrey Brinker, Vittorio Cristini	16
15	Tucatinib, palbociclib, and letrozole in HR+/HER2+ metastatic breast cancer: Report of phase IB safety cohort. 2019 ·Journal of Clinical Oncology ·Elena Shagisultanova, Pavani Chalasani, Ursa Brown‐Glaberman, William J. Gradishar, Andrew Brenner, Alison Stopeck, Dexiang Gao, (unknown), Peter Kabos, Virginia F. Borges	11
16	SGNLVA-002: Single-arm, open label phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally advanced or metastatic triple-negative breast cancer. 2019 ·Journal of Clinical Oncology ·Hyo S. Han, Carlos Alemany, Ursa Brown‐Glaberman, Timothy Pluard, Rajni Sinha, (unknown), Kathy S. Albain, Reva Basho, David D. Biggs, Valentina Boni, Sami Diab, Michaela L. Tsai, Katherine H. R. Tkaczuk, Yinghui Wang, Zejing Wang, Jane Meisel	26
17	Ribociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial 2018 ·Annals of Oncology ·Claudio Zamagni, Mario Campone, (unknown), Ursa Brown‐Glaberman, Paul Cottu, Alexander Ring, Janice Lu, Miguel Martín, Michelino De Laurentiis, (unknown), (unknown), (unknown), Hamdy A. Azim	0
18	Circulating Carbonic Anhydrase IX and Antiangiogenic Therapy in Breast Cancer 2016 ·Disease Markers ·Ursa Brown‐Glaberman, Marilyn Marron, Pavani Chalasani, Robert B. Livingston, Maria Iannone, Jennifer M. Specht, Alison Stopeck	16
19	HER2-targeted therapy for early-stage breast cancer: a comprehensive review. 2014 ·PubMed ·Ursa Brown‐Glaberman, Zoneddy Dayao, Melanie Royce	20
20	The role of targeted therapy and biomarkers in breast cancer treatment 2012 ·Clinical & Experimental Metastasis ·Alison Stopeck, Ursa Brown‐Glaberman, Hong Yuen Wong, Ben Ho Park, (unknown), William J. Gradishar, Clifford A. Hudis, Hope S. Rugo	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact